Ascentage Pharma initiated with a Buy at BTIG

BTIG analyst Jeet Mukherjee initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target The firm says the China-built biopharma’s “global relevance will become increasingly clear” through two key assets in the pipeline over the next one to two years – namely Olverembatinib, which is advancing through three Phase 3 programs, and Lisaftoclax, which has four registrational Phase 3 readouts expected in 2027.